| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Febantel is a prodrug that is metabolized to fenbendazole and then to oxfendazole, which are the active anthelmintic compounds. These active metabolites bind to beta-tubulin in parasitic nematodes, inhibiting microtubule polymerization. This disrupts essential cellular processes such as glucose uptake, nutrient transport, and cell division, leading to parasite death. Febantel targets beta-tubulin in susceptible parasites.
|
|---|---|
| ln Vitro |
In vitro, febantel is converted to its active metabolites, which demonstrate potent activity against various parasitic nematodes. The compound's anthelmintic activity is mediated through the inhibition of microtubule polymerization, as confirmed by in vitro assays using parasite cell cultures. Febantel's active metabolites show high affinity for beta-tubulin in susceptible parasites.
|
| ln Vivo |
In vivo, febantel is effective against a wide range of gastrointestinal nematodes, lungworms, and tapeworms in livestock, horses, and companion animals. It is administered orally and is well absorbed. The drug's broad-spectrum activity makes it a valuable anthelmintic in veterinary medicine. Febantel is used for the treatment and control of parasitic infections in various animal species.
|
| Enzyme Assay |
In non-cell-based biochemical assays, febantel's activity is evaluated by measuring its conversion to active metabolites and the binding of these metabolites to beta-tubulin. The inhibition of microtubule polymerization is assessed using biochemical methods that measure tubulin polymerization in the presence of the compound's metabolites. These assays confirm the compound's mechanism of action.
|
| Cell Assay |
In vitro cellular assays for febantel involve testing its effects on parasite cell cultures. Parasitic nematode cells or whole organisms are treated with febantel or its metabolites, and effects on cell viability, motility, and microtubule integrity are assessed. These assays confirm the compound's anthelmintic activity and mechanism of action.
|
| Animal Protocol |
In vivo animal studies for febantel are conducted primarily in livestock, horses, and companion animals. The compound is administered orally, and its efficacy against various parasitic infections is assessed by measuring fecal egg count reduction, parasite burden, and clinical improvement. These studies have established febantel's broad-spectrum anthelmintic activity.
|
| ADME/Pharmacokinetics |
Febantel is a prodrug that is metabolized in the liver and gastrointestinal tract to its active metabolites, fenbendazole and oxfendazole. The drug is well absorbed after oral administration and is distributed to various tissues. The active metabolites are eliminated primarily by renal excretion. The pharmacokinetic profile supports once or twice daily dosing.
|
| Toxicity/Toxicokinetics |
The most common side effects of febantel are mild and may include gastrointestinal disturbances such as vomiting or diarrhea. In rare cases, hypersensitivity reactions may occur. Febantel should be used with caution in pregnant or lactating animals, and appropriate withdrawal periods should be observed in food-producing animals to prevent drug residues in meat and milk.
|
| Additional Infomation |
Febantel is an aryl thioether. See also: Febantel; Praziquantel; Thiaphanidine dihydroxynaphthyl salt (component); Febantel; Praziquantel (component).
Febantel is a broad-spectrum anthelmintic prodrug used in veterinary medicine for the treatment of parasitic infections. It is metabolized to fenbendazole and oxfendazole, which bind to beta-tubulin and inhibit microtubule polymerization in parasites. Febantel is effective against gastrointestinal nematodes, lungworms, and tapeworms in livestock, horses, and companion animals. It is available in various formulations for oral administration. |
| Molecular Formula |
C20H22N4O6S
|
|---|---|
| Molecular Weight |
446.48
|
| Exact Mass |
446.126
|
| CAS # |
58306-30-2
|
| PubChem CID |
135449328
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Melting Point |
129-130ºC
|
| Index of Refraction |
1.598
|
| LogP |
2.36
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
31
|
| Complexity |
621
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C1C([H])=C([H])C([H])=C([H])C=1[H])C1C([H])=C([H])C(=C(C=1[H])N([H])C(C([H])([H])OC([H])([H])[H])=O)/N=C(\N([H])C(=O)OC([H])([H])[H])/N([H])C(=O)OC([H])([H])[H]
|
| InChi Key |
HMCCXLBXIJMERM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H22N4O6S/c1-28-12-17(25)21-16-11-14(31-13-7-5-4-6-8-13)9-10-15(16)22-18(23-19(26)29-2)24-20(27)30-3/h4-11H,12H2,1-3H3,(H,21,25)(H2,22,23,24,26,27)
|
| Chemical Name |
((2-((Methoxyacetyl)amino)-4-(phenylthio)phenyl)carbonimidoyl)bis(carbamic acid), dimethyl ester
|
| Synonyms |
Febantel Bay h-5757 Bay h 5757Bay h5757
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~223.97 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.60 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.60 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2397 mL | 11.1987 mL | 22.3974 mL | |
| 5 mM | 0.4479 mL | 2.2397 mL | 4.4795 mL | |
| 10 mM | 0.2240 mL | 1.1199 mL | 2.2397 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
